Evidence map›Paper›PMID 23403436›Full record

SynthesisCirculation. Heart failure2013

Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials.

Srinivas R Bapoje, Amit Bahia, John E Hokanson, Pamela N Peterson, Paul A Heidenreich, Joann Lindenfeld, Larry A Allen, Frederick A Masoudi

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Circulation. Heart failure, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Srinivas R BapojeDepartment of Medicine, Denver Health and Hospital Authority, Denver, CO, USA. srbapoje@uams.edu
Amit Bahia
John E Hokanson
Pamela N Peterson
Paul A Heidenreich
Joann Lindenfeld
Larry A Allen
Frederick A Masoudi
University of Colorado Anschutz Medical Campus · USVA Palo Alto Health Care System · USColorado School of Public Health · USDenver Health Medical Center · USHealth and Hospital Corporation · USUniversity of Colorado Denver · US

Funding

Addressing Gaps in Longitudinal Heart Failure Pharmacotherapy to Reduce RehospitaK23HL105896 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALLEN, LARRY ALEXANDER · 2011 to 2015
$676k
NHLBI NIH HHS K23 HL105896
6 · The paper itself

Abstract

backgroundSudden cardiac death (SCD) is an important cause of death in patients with left ventricular systolic dysfunction. Mineralocorticoid receptor antagonists (MRAs) may attenuate this risk. The objective of this meta-analysis was to assess the impact of MRAs on SCD in patients with left ventricular systolic dysfunction. METHODS AND

resultsWe systematically searched PubMed, EMBASE, Cochrane, and other databases through March 30, 2012, without language restrictions. We included trials that enrolled patients with left ventricular ejection fraction of ≤45%, randomized subjects to MRAs versus control and reported outcomes on SCD, total and cardiovascular mortality. Eight published trials that enrolled 11 875 patients met inclusion criteria. Of these, 6 reported data on SCD and cardiovascular mortality, and 7 reported data on total mortality. No heterogeneity was observed among the trials. Patients treated with MRAs had 23% lower odds of experiencing SCD compared with controls (odds ratio, 0.77; 95% confidence interval, 0.66-0.89; P=0.001). Similar reductions were observed in cardiovascular (0.75; 95% confidence interval, 0.68-0.84; P<0.001) and total mortality (odds ratio, 0.74; 95% confidence interval, 0.63-0.86; P<0.001). Although publication bias was observed, the results did not change after a trim and fill test, suggesting that the impact of this bias was likely insignificant.

conclusionsMRAs reduce the risk of SCD in patients with left ventricular systolic dysfunction. Comparative effectiveness studies of MRAs on SCD in usual care as well as studies evaluating the efficacy of other therapies to prevent SCD in patients receiving optimal MRA therapy are needed to guide clinical decision-making.

Indexed as

Death, Sudden, CardiacHumansMineralocorticoid Receptor AntagonistsOdds RatioRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSystoleTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftMineralocorticoid Receptor Antagonists

Identifiers

PMID23403436
PMCPMC3893922
OpenAlexW2132472087

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.